NCT00743288View on ClinicalTrials.gov

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

November 30, 2012

Study Completion Date

December 31, 2012

Conditions
Multiple Myeloma
Interventions
DRUG

Melphalan

Same as above

DRUG

Panobinostat

Trial Locations (4)

20817

Center for Cancer and Blood Disorders, Bethesda

80218

Rocky Mountain Cancer Centers - Denver Midtown, Denver

90069

James R. Berenson MD, Incorporated, West Hollywood

93309-0633

Comprehensive Blood and Cancer Center, Bakersfield

Sponsors

Lead Sponsor

Oncotherapeutics

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Oncotherapeutics

INDUSTRY

NCT00743288 - Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | Biotech Hunter | Biotech Hunter